HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

African-American Hair-Care Opportunity To Reach $774 Mil. By Year-End

This article was originally published in The Rose Sheet

Executive Summary

Mintel says despite growth in the market for hair care tailored to Black consumers, in many cases African-Americans’ needs are still not being met. “Part of the challenge is that many companies aren’t marketing their products to Blacks using the right casting and culturally relevant messaging,” the market intelligence firm suggests.

You may also be interested in...



L’Oreal To Enrich Its Multicultural Offering As Parent To Carol’s Daughter

Firm says the acquisition of natural-positioned hair- and skin-care marketer Carol’s Daughter will enhance its multicultural beauty portfolio, which currently includes SoftSheen-Carson at the mass level as well as salon brand Mizani. The announcement was met with a mixed reaction from the brand’s fans, with some welcoming the news and others concerned that product quality will be compromised.

P&G Looks To “Transform” Categories, But Ackman Presses For Results

CFO Jon Moeller says product launches will make “obsolete our existing categories and transform them in ways that create competitive advantage” for the firm. Activist investor Bill Ackman, however, says P&G is “vastly under-earning relative to its intrinsic earnings power.”

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel